Could a new drug halt hair loss from frontal fibrosing alopecia?
NCT ID NCT06240351
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This pilot study tests the safety and effectiveness of baricitinib, a drug that targets inflammation, in 15 women with active frontal fibrosing alopecia (FFA). FFA is a condition that causes scarring and permanent hair loss, mainly at the front of the scalp and eyebrows. The study measures changes in disease activity using a special scoring system and looks for improvements in symptoms like itching and redness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female at least 18 years of age, and able to provide informed consent * Females who are post-menopausal defined, as not have menses for at least 12 months without an alternative medical cause and elevated follicle stimulating hormone in the postmenopausal range as measured during screening * Have active FFA that has been diagnosed on or prior to screening visit. * Have LPPAI score equal to or greater than 5 at screening. * Have evidence of eyebrow loss at baseline * Have evidence of hairline recession at baseline * Have classic presentation with frontal loss of scalp hair * Negative screening for tuberculosis (Quantiferon Gold, T-spot) within 3 months prior to screening or at the screening visit. * Agree not to have a live vaccination during the study the exception is herpes zoster vaccine Exclusion Criteria: * Systemic treatments for FFA within 4 weeks of the baseline visit or 5 half lives whichever one is longer. (ex: finasteride, pioglitazone, hydroxychloroquine, or immunosuppressant medications, such as mycophenolate mofetil). * Dutasteride within the last 6 months * Have a LPPAI score less than 5 at screening * Immunocompromised and with risk factors concerning to investigator for study participation * Previous treatment with an oral JAK inhibitor * Any condition in the opinion of the investigator which would interfere with the study assessments or procedure * Subject is pregnant or breast feeding * Surgical intervention including face lifts and micro-blading on the treatment areas * Any intervention (facelifts micro blading) that could affect the treatment areas (i.e. scalp and eyebrows) * Laser or phototherapy intervention on the treatment areas * Have evidence of active TB or latent TB
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Frontal fibrosing alopecia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.